Tagged with China

Hong Kong With Hong Kong now host to a growing volume of public and private entities specializing in cell and gene therapy development, some market insiders spy great opportunities for the city, with its unique background context and characteristics, to play a role shaping the next wave of biomedicine discovery.   Dr…

Hong Kong Hong Kong has a burgeoning status within Greater China as an advanced therapy hub. The Special Administrative Region boasts clinical trial expertise, internationally aligned regulation, a lack of price caps, and the recently minted ability to produce cell and gene therapies within the city. This means that, today, more new…

Hong Kong Hong Kong’s unique history as a former British governate and current special status under the ‘one country, two systems’ administrative framework, endow it with many underlying advantages as a ‘talent magnet.’ From a professional standpoint, the city’s international connectivity, financial architecture, and efficient infrastructure already render it an appealing location…

China With nearly half of Chinese adults now suffering from myopia and age-related eye conditions on the rise, China is on the brink of an ophthalmology boom — a market set to more than double by 2031. While global players like Santen have taken an early lead, a new wave of…

China A summary of top stories from China’s pharma industry: Sciwind Biosciences presents promising trial data for its obesity contender; Simcere reaches approval for its Idorsia-partnered insomnia therapy; AstraZeneca inks AI-enabled research deal with CSPC Pharmaceuticals, and the FDA blocks clinical trials that export American’s cells to China. Sciwind’s GLP‑1 data…

China Swapping the predictability of venture capital for the high-stakes volatility of biotech entrepreneurship, John Zhu set out to build something few in China had dared: a globally oriented biopharma with the speed of a startup and the reach of an MNC. As Founder, CEO, and Chairman of Duality Biotherapeutics, Zhu…

Germany Once a little-known mRNA pioneer, BioNTech became a household name with its COVID-19 vaccine developed alongside Pfizer. But the German biotech is now pursuing an even bigger transformation — and China is at the heart of its strategy. Using vaccine proceeds to tap China’s booming life sciences ecosystem, BioNTech has…

Hong Kong In March 2024, the Advanced Therapy Product Good Manufacturing Practice Centre (ATP GMP Centre) at the Chinese University of Hong Kong’s (CUHK) Institute of Biotechnology (HKIB) became the first university-led centre within the special administrative region to receive certification for cell and gene therapy manufacturing and a license as an…

China Ye Liu, CEO and cofounder of OcuMension Therapeutics, speaks about the challenges and triumphs of running one of China’s most ambitious ophthalmology-focused biopharmaceutical companies. Launched with USD 5 million and no initial products, OcuMension now leads in China’s ophthalmology drug development, maintains rapid growth, and is preparing for global reach.…

China Building a biotech from the ground up is rarely the next step for someone who has led multinational pharmaceutical giants. Yet that was the challenge Pony Lu accepted when he took the helm at VISEN Pharmaceuticals. Tasked with shaping the company from its inception, he brought not only decades of…

China 2024 marks a moment of inflection for Harbour BioMed, as the company collect the rewards of a strong global execution. In this interview, Dr Jingsong Wang reflects on the strategic, scientific, and operational advances shaping the company’s trajectory. With its proprietary HCAb platform at the core, Harbour BioMed is extending…

Switzerland Juergen Nelis, CEO of BGG World Holding, discusses the company’s strategic growth and evolving approach to sustainability, market expansion, and product innovation. He highlights key initiatives such as expanding production capabilities outside of China and refining BGG’s global leadership structure, while also addressing the challenges posed by geopolitical factors and…